Clinical trial demonstrates semaglutide's benefits on infection risks in high-risk type 2 diabetes patients, suggesting wider applications.
Semaglutide reduced risks of infection SAEs, hospitalization due to infection, and all-cause death with greater benefit among those with poorer glycemic control and greater baseline albuminuria. These findings support potential clinical benefits of semaglutide beyond kidney, CV, and metabolic outcomes in high-risk patients with T2D and CKD.
No takes yet. Share an insight, caveat, or question.
Rayner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: